Orexigen Therapeutics Inc. (Nasdaq: OREX) halted mid-stage clinical trials of two experimental weight loss drugs in order to have enough resources to continue late-stage studies. The stock price plummeted $2.41 to $2.99.
Orexigen Therapeutics Halts Drug Trials
December 05, 2008 at 14:04 PM EST
